Tryptamine Therapeutics (ASX:TYP) says it has received positive results from its recently completed Phase 2a clinical trial, which was conducted in collaboration with the University of Michigan.
The company said university researchers recently presented the results at the International Association for the Study of Pain 2024 World Congress in the Netherlands.
The trial was designed to evaluate TRP-8802 (oral psilocybin) in conjunction with psychotherapy in patients with fibromyalgia, a condition associated with widespread pain and comorbidities that significantly impact daily living and patient well-being.
The company said that while the study was small, psilocybin-assisted therapy was safe and well tolerated. It said the therapy reported positive effects on multiple domains, including pain, pain interference, sleep, fatigue and anxiety.
CEO Jason Carroll said, “We are very excited about the results from the Phase 2a clinical trial in collaboration with the University of Michigan. Fibromyalgia is a complex and widespread condition, impacting one million Australians, and imposes a large emotional, physical and economic burden on every sufferer.
"Despite this, fibromyalgia sufferers have very limited success with current treatments, often resort to the use of opioids and many of these have highly limiting and wide-ranging side effects associated with their use.”
“While still early, these results highlight that psychedelic-assisted therapy may achieve an improved patient outcome through treating the cause of fibromyalgia rather than the limited relief to select symptoms provided from the treatment choices presently open to them."
Mr Carroll said the company would undertake further analysis of the study results in partnership with University of Michigan researchers.